DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease.

When we ran a binary logistic regression analysis with group (LBD versus atypical PS) as a dependent variable and both DDC level and SAA status as independent predictors, we found that SAA was a highly significant variable that discriminated LBD from atypical PS(SAA: β = 5, P = 3.6 × 10 −11 , AUC = 0.95, sensitivity = 0.93, specificity = 0.93), in contrast to DDC ( β = 0.6, P = 0.01, AUC = 0.73, sensitivity = 0.37, specificity = 0.89) (Extended Data Fig. 4a ).

also in 132,142 other papers